PMID- 28195139
OWN - NLM
STAT- MEDLINE
DCOM- 20180516
LR  - 20181113
IS  - 1740-634X (Electronic)
IS  - 0893-133X (Print)
IS  - 0893-133X (Linking)
VI  - 42
IP  - 11
DP  - 2017 Oct
TI  - Altered Insula Connectivity under MDMA.
PG  - 2152-2162
LID - 10.1038/npp.2017.35 [doi]
AB  - Recent work with noninvasive human brain imaging has started to investigate the 
      effects of 3,4-methylenedioxymethamphetamine (MDMA) on large-scale patterns of 
      brain activity. MDMA, a potent monoamine-releaser with particularly pronounced 
      serotonin- releasing properties, has unique subjective effects that include: 
      marked positive mood, pleasant/unusual bodily sensations and pro-social, empathic 
      feelings. However, the neurobiological basis for these effects is not properly 
      understood, and the present analysis sought to address this knowledge gap. To do 
      this, we administered MDMA-HCl (100 mg p.o.) and, separately, placebo (ascorbic 
      acid) in a randomized, double-blind, repeated-measures design with twenty-five 
      healthy volunteers undergoing fMRI scanning. We then employed a measure of global 
      resting-state functional brain connectivity and follow-up seed-to-voxel analysis 
      to the fMRI data we acquired. Results revealed decreased right insula/salience 
      network functional connectivity under MDMA. Furthermore, these decreases in right 
      insula/salience network connectivity correlated with baseline trait anxiety and 
      acute experiences of altered bodily sensations under MDMA. The present findings 
      highlight insular disintegration (ie, compromised salience network membership) as 
      a neurobiological signature of the MDMA experience, and relate this brain effect 
      to trait anxiety and acutely altered bodily sensations-both of which are known to 
      be associated with insular functioning.
FAU - Walpola, Ishan C
AU  - Walpola IC
AD  - Department of Psychiatry, McGill University Faculty of Medicine, McGill 
      University, Montreal, Quebec, Canada.
FAU - Nest, Timothy
AU  - Nest T
AD  - Department of Psychiatry, McGill University Faculty of Medicine, McGill 
      University, Montreal, Quebec, Canada.
FAU - Roseman, Leor
AU  - Roseman L
AD  - Division of Brain Sciences, Faculty of Medicine, Centre for 
      Neuropsychopharmacology, Imperial College London, London, UK.
FAU - Erritzoe, David
AU  - Erritzoe D
AD  - Division of Brain Sciences, Faculty of Medicine, Centre for 
      Neuropsychopharmacology, Imperial College London, London, UK.
FAU - Feilding, Amanda
AU  - Feilding A
AD  - The Beckley Foundation, Oxford, UK.
FAU - Nutt, David J
AU  - Nutt DJ
AD  - Division of Brain Sciences, Faculty of Medicine, Centre for 
      Neuropsychopharmacology, Imperial College London, London, UK.
FAU - Carhart-Harris, Robin L
AU  - Carhart-Harris RL
AD  - Division of Brain Sciences, Faculty of Medicine, Centre for 
      Neuropsychopharmacology, Imperial College London, London, UK.
LA  - eng
GR  - Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20170214
PL  - England
TA  - Neuropsychopharmacology
JT  - Neuropsychopharmacology : official publication of the American College of 
      Neuropsychopharmacology
JID - 8904907
RN  - 0 (Hallucinogens)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Adult
MH  - Brain Mapping
MH  - Cerebral Cortex/diagnostic imaging/*drug effects
MH  - Double-Blind Method
MH  - Female
MH  - Follow-Up Studies
MH  - Hallucinogens/*pharmacology
MH  - Humans
MH  - Image Processing, Computer-Assisted
MH  - Linear Models
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*pharmacology
MH  - Nerve Net/diagnostic imaging/*drug effects
MH  - Rest
MH  - Young Adult
PMC - PMC5603811
EDAT- 2017/02/15 06:00
MHDA- 2018/05/17 06:00
PMCR- 2018/10/01
CRDT- 2017/02/15 06:00
PHST- 2016/05/22 00:00 [received]
PHST- 2017/02/05 00:00 [revised]
PHST- 2017/02/08 00:00 [accepted]
PHST- 2017/02/15 06:00 [pubmed]
PHST- 2018/05/17 06:00 [medline]
PHST- 2017/02/15 06:00 [entrez]
PHST- 2018/10/01 00:00 [pmc-release]
AID - npp201735 [pii]
AID - 10.1038/npp.2017.35 [doi]
PST - ppublish
SO  - Neuropsychopharmacology. 2017 Oct;42(11):2152-2162. doi: 10.1038/npp.2017.35. 
      Epub 2017 Feb 14.